À propos de cet article

Citez

1. Wang R, Wan L, Li Q, Liu X, Huang Y. Chemiluminescence of synephrine based on the cerium(IV) – rhodamine B system. Luminescence. 2007;22(2):140-6.10.1002/bio.937 Search in Google Scholar

2. Watson DG, Midgley JM, Chen RN, Huang W, Bain GM, McDonald NM, et al. Analysis of biogenic amines and their metabolites in biological tissues and fluids by gas chromatography - negative ion chemical ionization mass spectrometry (GC-NICIMS). J Pharm Biomed Anal. 1990;8(8-12):899-904.10.1016/0731-7085(90)80139-G Search in Google Scholar

3. Stohs SJ. Safety, Efficacy, and Mechanistic Studies Regarding Citrus aurantium (Bitter Orange) Extract and p-Synephrine. Phytother Res. 2017;31(10):1463-74.10.1002/ptr.5879 Search in Google Scholar

4. Rossato LG, Costa VM, Limberger RP, Bastos Mde L, Remião F. Synephrine: from trace concentrations to massive consumption in weight-loss. Food Chem Toxicol. 2011;49(1):8-16.10.1016/j.fct.2010.11.007 Search in Google Scholar

5. Xu WW, Zheng C, Huang Y, Chen W, Yang Q, Ren J, et al. Synephrine hydrochloride suppresses esophageal cancer tumor growth and metastatic potential through inhibition of Galectin-3-AKT/ERK signaling. Agric Food Chem. 2018;66(35):9248-58.10.1021/acs.jafc.8b04020 Search in Google Scholar

6. Roh K, Kim I, Kim Y, Lee M, Lee J, Jung E, et al. Synephrine inhibits eotaxin-1 expression via the STAT6 signaling pathway. Molecules. 2014;19(8):11883-95.10.3390/molecules190811883 Search in Google Scholar

7. Wu Q, Li R, Soromou LW, Chen N, Yuan X, Sun G, et al. p-Synephrine suppresses lipopolysaccharide-induced acute lung injury by inhibition of the NF-κB signaling pathway. Inflamm Res. 2014; 63(6):429-39.10.1007/s00011-014-0715-7 Search in Google Scholar

8. Kim KW, Kim HD, Jung JS, Woo RS, Kim HS, Suh HW, et al. Characterization of antidepressant-like effects of p-synephrine stereoisomers. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(1): 21-26.10.1007/s002100100416 Search in Google Scholar

9. Magos GA, Vidrio H, Reynolds WF, Enriguez RG. Pharmacology of Casimiroa edulis IV. Hypotensive effects of compounds isolated from methanolic extracts in rats and guinea pigs. J Ethnopharmacol. 1999;64(1):35-44.10.1016/S0378-8741(98)00101-9 Search in Google Scholar

10. Hibino T, Yuzurihara M, Kase Y, Tekeda A. Synephrine, a component of evodiae fructus, constricts isolated rat aorta via adrenergic and serotonergic receptors. J Pharmacol Sci. 2009;111(1):73-81.10.1254/jphs.09077FP19721332 Search in Google Scholar

11. Huang YT, Lin HC, Chang YY, Yang YY, Lee SD, Hong CY. Hemodynamic effects of synephrine treatment in portal hypertensive rats. Jpn J Pharmacol. 2001;85(2):183-8.10.1254/jjp.85.18311286401 Search in Google Scholar

12. Stohs SJ, Shara M, Ray SD. p-Synephrine, ephedrine, p-octopamine and m-synephrine: Comparative mechanistic, physiological and pharmacological properties. Phytother Res. 2020;34(8):1838-46.10.1002/ptr.6649749638732101364 Search in Google Scholar

13. Hong NY, Cui ZG, Kang HK, Lee DH, Lee YK, Park DB. p-Synephrine stimulates glucose consumption via AMPK in L6 skeletal muscle cells. Biochem Biophys Res Commun. 2012;418(4):720-4.10.1016/j.bbrc.2012.01.08522306011 Search in Google Scholar

14. Brown CM, McGrath JC, Midgley JM, Muir AG, O’Brien JW, Thonoor CM, et al. Activities of octopamine and synephrine stereoisomers on α-adrenoreceptors. Br J Pharmacol. 1988;93(2): 417-29.10.1111/j.1476-5381.1988.tb11449.x18538042833972 Search in Google Scholar

15. Takagi M, Kimura K, Nakashima KI, Hirai T, Inoue M. Induction of beige adipocytes by naturally occurring β3-adrenoceptor agonist p-synephrine. Eur J Pharmacol. 2018;836:67-74.10.1016/j.ejphar.2018.08.01130120922 Search in Google Scholar

16. Shara M, Stohs SJ, Smadi, MM. Safety evaluation of p-synephrine following 15 days of oral administration to healthy subjects. A clinical study. Phytother Res. 2018;32(1):125-31.10.1002/ptr.595629130542 Search in Google Scholar

17. Cui Z, Lee Y, Lee Y, Park D. p-Synephrine suppresses glucose production but not lipid accumulation in H4IIE liver cells. J Med Food. 2015;18(1):76-82.10.1089/jmf.2013.3133428183825379695 Search in Google Scholar

18. Stohs SJ, Badmaev V. A review of natural stimulant and non-stimulant thermogenic agents. Phytother Res. 2016;30(5):732-40.10.1002/ptr.5583506754826856274 Search in Google Scholar

19. Maldonado MR, Bracht L, de Sá-Nakanishi AB, Correa RCG, Comar JF, Peralta RM, et. al. Actions of p-synephrine on hepatic enzyme activities linked to carbohydrate metabolism and ATP levels in vivo and in the perfused rat liver. Cell Biochem Funct. 2018;36(1):4-12.10.1002/cbf.331129270996 Search in Google Scholar

20. Taslimi P, Akıncıoglu H, Gülçin İ. Synephrine and phenylephrine act as α-Amylase, α-Glycosidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase enzymes inhibitors. J Biochem Mol Toxicol. 2017;31(11).10.1002/jbt.2197328800181 Search in Google Scholar

21. Gutiérrez-Hellín J, Del Coso J. Effects of p-Synephrine and caffeine ingestion on substrate oxidation during exercise. Med Sci Sports Exerc. 2018;50(9):1899-906.10.1249/MSS.000000000000165329727404 Search in Google Scholar

22. Guo LX, Chen G, Yin ZY, Zhang YH, Zheng XX. p-Synephrine exhibits anti-adipogenic activity by activating the Akt/GSK3β signaling pathway in 3T3-L1 adipocytes. J Food Biochem. 2019;43(11).10.1111/jfbc.1303331486092 Search in Google Scholar

23. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7(1):79-88.10.1111/j.1467-789X.2006.00195.x16436104 Search in Google Scholar

24. Zheng X, Guo L, Wang D, Deng X. p-Synephrine: a novel agonist for neuromedin U2 receptor. Biol Pharm Bull. 2014;37(5):764-70.10.1248/bpb.b13-0078824598981 Search in Google Scholar

25. de Oliveira AL, Comar JF, de Sá-Nakanishi AB, Peralta RM, Bracht A. The action of p-synephrine on hepatic carbohydrate metabolism and respiration occurs via both Ca2+ –mobilization and cAMP production. Mol Cell Biochem. 2014;388(1-2):135-47.10.1007/s11010-013-1905-224287564 Search in Google Scholar

26. Stohs SJ, Preuss HG, Keith SC, et al. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci. 2011;8(4):295-301.10.7150/ijms.8.295308517621537493 Search in Google Scholar

27. Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci. 2012;9(7):527-38.10.7150/ijms.4446344497322991491 Search in Google Scholar

28. Stohs SJ, Preuss HG, Shara M. The Safety of Citrus aurantium (Bitter Orange) and its Primary Protoalkaloid p-Synephrine. Phytother Res. 2011;25(10):1421-8.10.1002/ptr.349021480414 Search in Google Scholar

29. Wierzejska R. Dietary supplements – panacea to contemporary health problems, or the triumph of advertisement? Med Rodz. 2017; 20(2):136-42. Search in Google Scholar

30. Mercader J, Wanecq E, Chen J, Carpene C. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J Physiol Biochem. 2011;67(3):443-52.10.1007/s13105-011-0078-221336650 Search in Google Scholar

31. Arbo MD, Schmitt GC, Limberger MF, Charão MF, Moro AM, Ribeiro GL, et al. Subchronic toxicity of Citrus aurantium L. (Rutaceae) extract and p-synephrine in mice. Regul Toxicol Pharmacol. 2009;54(2);114-7.10.1016/j.yrtph.2009.03.00119275924 Search in Google Scholar

32. Song DK, Suh HW, Jung JS, Wie MB, Son KH, Kim YH. Antidepressant-like effects of p-synephrine in mouse models of immobility tests. Neurosci Lett. 1996;214(2-3):107-10.10.1016/0304-3940(96)12895-0 Search in Google Scholar

33. Deshmukh NS, Stohs SJ, Magar CC, Kadam SB. Citrus aurantium (bitter orange) extract: Safety assessment by acute and 14-day oral toxicity studies in rats and the Ames Test for mutagenicity. Regul Toxicol Pharmacol. 2017;90:318-27.10.1016/j.yrtph.2017.09.02728966104 Search in Google Scholar

eISSN:
2300-6676
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Medicine, Clinical Medicine, other, Pharmacology, Toxicology, Pharmacy